DelMar Pharmaceuticals (NASDAQ:DMPI) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, August 2nd.
Separately, HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 23rd.
Shares of DMPI stock traded down $0.02 on Thursday, reaching $0.52. 79,894 shares of the stock were exchanged, compared to its average volume of 98,104. DelMar Pharmaceuticals has a one year low of $0.47 and a one year high of $2.29.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings data on Tuesday, May 15th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). equities research analysts predict that DelMar Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
See Also: Understanding Stock Ratings
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.